-
1.发明专利
公开(公告)号：JP2012111761A
公开(公告)日：2012-06-14
申请号：JP2012000042
申请日：2012-01-04
Applicant: Abbott Lab , アボット・ラボラトリーズAbbott Laboratories
Inventor： PACE JENNIFER M , TIETJE KARIN , DART MICHAEL J , MEYER MICHAEL D
IPC: C07D209/12 , A61K31/404 , A61K31/4178 , A61K31/422 , A61K31/427 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/5377 , A61K31/55 , A61P9/00 , A61P11/00 , A61P19/02 , A61P25/00 , A61P25/04 , A61P29/00 , A61P35/00 , A61P37/02 , A61P37/06 , A61P43/00 , C07D401/06 , C07D403/06 , C07D405/06 , C07D409/06 , C07D413/06 , C07D417/06
CPC classification number: C07D403/06 , C07D209/12 , C07D401/06 , C07D405/06 , C07D409/06 , C07D413/06 , C07D417/06
Abstract: PROBLEM TO BE SOLVED: To provide a cannabinoid receptor CBselective ligand useful for treatment of sharp pain.SOLUTION: A novel compound expressed by formula (I) is provided. In the formula, Rrepresents a heteroarylalkyl or the like; Ris selected from the group consisting of hydrogen, alkyl and the like; Rrepresents 2,2,3,3-tetramethyl cyclopropyl or the like; R, R, Rand Rare independently selected from hydrogen, alkenyl, carboxy, cyano and the like.
Abstract translation: 待解决的问题：提供可用于治疗急性疼痛的大麻素受体CB
2 选择性配体。 解决方案：提供由式（I）表示的新型化合物。 在该式中，R 1 表示杂芳基烷基等; R 3 选自氢，烷基等; R 4 表示2,2,3,3-四甲基环丙基等; R 5 ，R 6 ，R 7 ，R 8 独立地选自氢，烯基，羧基，氰基等。 版权所有（C）2012，JPO＆INPIT -
公开(公告)号：WO2007084535A3
公开(公告)日：2007-09-07
申请号：PCT/US2007001193
申请日：2007-01-17
Applicant: ABBOTT LAB , VERLINDEN MARIA-HELENA , MEYER MICHAEL D , DECKER MICHAEL W , SULLIVAN JAMES P , BUNNELLE WILLIAM H
Inventor： VERLINDEN MARIA-HELENA , MEYER MICHAEL D , DECKER MICHAEL W , SULLIVAN JAMES P , BUNNELLE WILLIAM H
IPC: A61K31/40 , A61K31/435 , A61P25/28
CPC classification number: A61K31/40 , A61K31/435 , A61K31/4439 , G01N33/944 , G01N2500/00
Abstract: The invention relates to neuronal nicotinic receptor ligands, methods of identifying such ligands for neuronal nicotinic receptor modulation, particularly such ligands demonstrating beneficial side effect tolerability, and methods of using such neuronal nicotinic receptor ligands to provide pharmaceutical compositions and products.
Abstract translation: 本发明涉及神经元烟碱受体配体，鉴定神经元烟碱受体调节的这种配体的方法，特别是显示出有益的副作用耐受性的这种配体，以及使用这种神经元烟碱受体配体提供药物组合物和产品的方法。
-
公开(公告)号：WO2008063781A2
公开(公告)日：2008-05-29
申请号：PCT/US2007081263
申请日：2007-10-12
Applicant: ABBOTT LAB , CARROLL WILLIAM A , DART MICHAEL J , KOLASA TEODOZYJ , MEYER MICHAEL D , PATEL MEENA V , WANG XUEQING
Inventor： CARROLL WILLIAM A , DART MICHAEL J , KOLASA TEODOZYJ , MEYER MICHAEL D , PATEL MEENA V , WANG XUEQING
IPC: C07D277/24 , C07D277/30 , C07D277/60 , C07D277/64 , C07D417/06
CPC classification number: C07D277/56 , C07D277/24 , C07D277/26 , C07D277/30 , C07D277/60 , C07D277/64 , C07D285/12 , C07D417/04 , C07D417/06 , C07D513/04
Abstract: The present invention relates to compounds of formula (I), wherein A, E, L2, R1, R3, R4 and R5 are as defined in the herein, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
Abstract translation: 本发明涉及式（I）化合物，其中A，E，L2，R1，R3，R4和R5如本文所定义，包含这些化合物的组合物，以及使用这些化合物和组合物治疗病症和障碍的方法 。
-
4.发明申请TERTIARY AND SECONDARY AMINES AS ALPHA-2 ANTAGONISTS AND SEROTONIN UPTAKE INHIBITORS 审中-公开碱性和二级氨基酸作为ALPHA-2拮抗剂和丝氨酸摄取抑制剂
公开(公告)号：WO9312754A3
公开(公告)日：2000-10-12
申请号：PCT/US9210794
申请日：1992-12-14
Applicant: ABBOTT LAB , MEYER MICHAEL D , DEBERNARDIS JOHN F , PRASAD RAJNANDAN , SIPPY KEVIN B , TIETJE KARIN R
Inventor： MEYER MICHAEL D , DEBERNARDIS JOHN F , PRASAD RAJNANDAN , SIPPY KEVIN B , TIETJE KARIN R
IPC: C07D317/58 , A61K31/135 , A61K31/165 , A61K31/352 , A61K31/357 , A61K31/36 , A61K31/382 , A61K31/4035 , A61K31/404 , A61K31/416 , A61K31/4184 , A61K31/423 , A61K31/4245 , A61K31/428 , A61K31/433 , A61K31/47 , A61K31/472 , A61K31/498 , A61K31/538 , A61K31/5415 , A61P9/00 , A61P9/10 , A61P9/12 , A61P25/00 , A61P25/06 , A61P25/18 , A61P25/24 , A61P25/28 , A61P25/30 , A61P27/06 , A61P43/00 , C07C217/58 , C07C217/74 , C07D209/08 , C07D209/14 , C07D209/44 , C07D209/48 , C07D215/12 , C07D217/02 , C07D217/04 , C07D231/56 , C07D235/06 , C07D235/14 , C07D241/42 , C07D263/56 , C07D263/58 , C07D265/36 , C07D271/08 , C07D275/04 , C07D277/64 , C07D277/68 , C07D277/82 , C07D279/02 , C07D279/10 , C07D279/16 , C07D285/14 , C07D307/78 , C07D307/79 , C07D311/58 , C07D311/76 , C07D319/08 , C07D319/18 , C07D327/04 , C07D333/54 , C07D333/58 , C07D333/72 , C07D335/06 , C07D405/12 , C07D407/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D301/79 , A61K31/34 , A61K31/38 , C07D307/83 , C07D307/87 , C07D307/88 , C07D333/64
CPC classification number: C07D209/48 , C07C217/74 , C07C2602/10 , C07D209/08 , C07D209/14 , C07D209/44 , C07D215/12 , C07D217/02 , C07D235/06 , C07D241/42 , C07D263/56 , C07D263/58 , C07D277/64 , C07D277/68 , C07D277/82 , C07D307/79 , C07D327/04 , C07D333/54 , C07D333/58 , C07D333/72 , C07D405/12 , C07D407/12 , C07D409/12 , C07D413/10 , C07D417/12
Abstract: The present invention provides an amine compound of formula (I) or a pharmaceutically acceptable salt thereof which is an antagonist for alpha-2 adrenoreceptors and which inhibits serotonin (5-hydroxytryptamine, 5-HT) uptake.
Abstract translation: 本发明提供了式（I）的胺化合物或其药学上可接受的盐，其是α-2肾上腺素受体的拮抗剂并且其抑制5-羟色胺（5-羟色胺，5-HT）摄取。
-
5.发明申请2-IMIN0IS0THIAZ0LE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS 审中-公开作为CANNABINOID受体配体的2-IMIN0IS0THIAZ0LE衍生物
公开(公告)号：WO2008130953A3
公开(公告)日：2008-12-11
申请号：PCT/US2008060400
申请日：2008-04-16
Applicant: ABBOTT LAB , CARROLL WILLIAM A , MEYER MICHAEL D
Inventor： CARROLL WILLIAM A , MEYER MICHAEL D
IPC: C07D275/02 , A61K31/425 , A61P9/00 , A61P11/00 , A61P25/00 , A61P29/00 , A61P35/00 , A61P37/00 , C07D275/04 , C07D417/04 , C07D417/06 , C07D417/12 , C07D513/04 , C07D513/10
CPC classification number: A61K31/425 , A61K31/427 , A61K31/429 , A61K31/4436 , A61K31/4725 , A61K31/5377 , C07D275/02 , C07D275/04 , C07D417/04 , C07D417/06 , C07D417/12 , C07D513/04 , C07D513/10 , Y02P20/582
Abstract: The present application relates to isothiazolylidene containing compounds of Formula (I) wherein R1, R2, R3, R4, and L are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
Abstract translation: 本申请涉及含有异噻唑基的式（I）化合物，其中R 1，R 2，R 3，R 4和L如说明书中所定义，包含这些化合物的组合物，以及使用这些化合物和组合物治疗病症和障碍的方法。
-
Patent Agency Ranking
公开(公告)号：WO0007997A8
公开(公告)日：2000-05-04
申请号：PCT/US9917739
申请日：1999-08-06
Applicant: ABBOTT LAB
Inventor： ALTENBACH ROBERT J , MEYER MICHAEL D , KERWIN JAMES F JR , HOLLADAY MARK W , KHILEVICH ALBERT , KOLASA TEODOZYJ , ROHDE JEFFREY , CARROLL WILLIAM A
IPC: C07D233/64 , A61K31/4164 , A61K31/4178 , A61K31/421 , A61K31/426 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/454 , A61K31/4709 , A61K31/4725 , A61P13/02 , A61P15/00 , A61P25/02 , A61P43/00 , C07D233/38 , C07D233/54 , C07D233/61 , C07D233/66 , C07D233/84 , C07D263/32 , C07D263/48 , C07D277/20 , C07D277/28 , C07D277/40 , C07D401/10 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/12 , C07D413/12 , C07D417/12
CPC classification number: C07D233/64 , C07D233/84 , C07D401/12 , C07D403/12 , C07D405/04 , C07D409/12 , C07D417/12
Abstract: Compounds having formula (I) are useful in treating diseases prevented by or ameliorated with alpha 1A agonists. Also disclosed are alpha 1A agonist compositions and a method of activating alpha 1 adrenoceptors in a mammal.
Abstract translation: 具有式（I）的化合物可用于治疗α1A激动剂所预防或改善的疾病。 还公开了α1A激动剂组合物和激活哺乳动物中α1肾上腺素能受体的方法。
-
7.发明公开TERTIARY AND SECONDARY AMINES AS ALPHA-2 ANTAGONISTS AND SEROTONIN UPTAKE INHIBITORS. 失效TERTIÄREUNDSEKUNDÄREAMINE ALS ALPHA-2 ANTAGONISTEN UND SEROTONINAUFNAHMEINHIBITOREN。
公开(公告)号：EP0646112A4
公开(公告)日：1997-04-02
申请号：EP93901313
申请日：1992-12-14
Applicant: ABBOTT LAB
Inventor： MEYER MICHAEL D , DEBERNARDIS JOHN F , PRASAD RAJNANDAN , SIPPY KEVIN B , TIETJE KARIN R
IPC: C07D317/58 , A61K31/135 , A61K31/165 , A61K31/352 , A61K31/357 , A61K31/36 , A61K31/382 , A61K31/4035 , A61K31/404 , A61K31/416 , A61K31/4184 , A61K31/423 , A61K31/4245 , A61K31/428 , A61K31/433 , A61K31/47 , A61K31/472 , A61K31/498 , A61K31/538 , A61K31/5415 , A61P9/00 , A61P9/10 , A61P9/12 , A61P25/00 , A61P25/06 , A61P25/18 , A61P25/24 , A61P25/28 , A61P25/30 , A61P27/06 , A61P43/00 , C07C217/58 , C07C217/74 , C07D209/08 , C07D209/14 , C07D209/44 , C07D209/48 , C07D215/12 , C07D217/02 , C07D217/04 , C07D231/56 , C07D235/06 , C07D235/14 , C07D241/42 , C07D263/56 , C07D263/58 , C07D265/36 , C07D271/08 , C07D275/04 , C07D277/64 , C07D277/68 , C07D277/82 , C07D279/02 , C07D279/10 , C07D279/16 , C07D285/14 , C07D307/78 , C07D307/79 , C07D311/58 , C07D311/76 , C07D319/08 , C07D319/18 , C07D327/04 , C07D333/54 , C07D333/58 , C07D333/72 , C07D335/06 , C07D405/12 , C07D407/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D339/00 , A61K31/00
CPC classification number: C07D209/48 , C07C217/74 , C07C2602/10 , C07D209/08 , C07D209/14 , C07D209/44 , C07D215/12 , C07D217/02 , C07D235/06 , C07D241/42 , C07D263/56 , C07D263/58 , C07D277/64 , C07D277/68 , C07D277/82 , C07D307/79 , C07D327/04 , C07D333/54 , C07D333/58 , C07D333/72 , C07D405/12 , C07D407/12 , C07D409/12 , C07D413/10 , C07D417/12
-
公开(公告)号：AU773795B2
公开(公告)日：2004-06-03
申请号：AU2856900
申请日：2000-01-25
Applicant: ABBOTT LAB
Inventor： BUNNELLE WILLIAM H , CRISTINA DANIELA BARLOCCO , DAANEN JEROME F , DART MICHAEL J , MEYER MICHAEL D , RYTHER KEITH B , SCHRIMPF MICHAEL R , SIPPY KEVIN B , TOUPENCE RICHARD B
IPC: A61K31/00 , A61K31/407 , A61K31/4355 , A61K31/4365 , A61K31/439 , A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/497 , A61K31/501 , A61K31/502 , A61P9/10 , A61P15/10 , A61P25/00 , A61P25/02 , A61P25/06 , A61P25/08 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30 , C07D401/08 , C07D471/08 , C07D487/08 , C07D491/048 , C07D495/04 , C07D519/00 , A61K31/395
Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof wherein: V is selected from the group consisting of a covalent bond and CH2; W is selected from the group consisting of a covalent bond, CH2 and CH2CH2; X is selected from the group consisting of a covalent bond and CH2; Y is selected from the group consisting of a covalent bond, CH2 and CH2CH2; Z is selected from the group consisting of CH2 and CH2CH2, and CH2CH2CH2; L1 is selected from the group consisting of a covalent bond and (CH2)n; n is 1-5; R1 is selected from the group consisting of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), and (l); R2 is selected from the group consisting of hydrogen, alkoxycarbonyl, alkyl, aminoalkyl, aminocarbonylalkyl, benzyloxycarbonyl, cyanoalkyl, dihydro-3-pyridinylcarbonyl, hydroxy, hydroxyalkyl, phenoxycarbonyl, and -NH2; are useful for controlling synaptic transmission in mammal.
-
公开(公告)号：SK283580B6
公开(公告)日：2003-09-11
申请号：SK71799
申请日：1997-12-04
Applicant: ABBOTT LAB
Inventor： MEYER MICHAEL D , ALTENBACH ROBERT J , BASHA FATIMA , CARROLL WILLIAM A , DRIZIN IRENE , KERWIN JAMES F , WENDT MICHAEL D , HAIGHT ANTHONY R , ZHANG WEIJIANG
IPC: A61K31/517 , A61K31/519 , A61P13/08 , A61P13/10 , A61P15/04 , A61P43/00 , C07D207/26 , C07D311/58 , C07D491/04 , C07D491/052 , C07D495/04 , C07D519/00 , A61K31/415
Abstract: The present invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein W is a bicyclic heterocyclic ring system. The compounds are 'alpha'-1 adrenergic antagonists and are useful in the treatment of BPH; also disclosed are 'alpha'-1 antagonist compositions and a method for antagonising 'alpha'-1 adrenoreceptors and treating BPH.
-
公开(公告)号：ZA200105835B
公开(公告)日：2002-10-16
申请号：ZA200105835
申请日：2001-07-16
Applicant: ABBOTT LAB
Inventor： BUNNELLE WILLIAM H , DAANEN JEROME F , MEYER MICHAEL D , SCHRIMPF MICHAEL R , TOUPENCE RICHARD B , CRISTINA DANIELA BARLOCCO , DART MICHAEL J , RYTHER KEITH B , SIPPY KEVIN B
IPC: A61K31/00 , A61K31/407 , A61K31/4355 , A61K31/4365 , A61K31/439 , A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/497 , A61K31/501 , A61K31/502 , A61P9/10 , A61P15/10 , A61P25/00 , A61P25/02 , A61P25/06 , A61P25/08 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30 , C07D401/08 , C07D471/08 , C07D487/08 , C07D491/048 , C07D495/04 , C07D519/00 , C07D , A61K , A61P
Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof wherein: V is selected from the group consisting of a covalent bond and CH2; W is selected from the group consisting of a covalent bond, CH2 and CH2CH2; X is selected from the group consisting of a covalent bond and CH2; Y is selected from the group consisting of a covalent bond, CH2 and CH2CH2; Z is selected from the group consisting of CH2 and CH2CH2, and CH2CH2CH2; L1 is selected from the group consisting of a covalent bond and (CH2)n; n is 1-5; R1 is selected from the group consisting of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), and (l); R2 is selected from the group consisting of hydrogen, alkoxycarbonyl, alkyl, aminoalkyl, aminocarbonylalkyl, benzyloxycarbonyl, cyanoalkyl, dihydro-3-pyridinylcarbonyl, hydroxy, hydroxyalkyl, phenoxycarbonyl, and -NH2; are useful for controlling synaptic transmission in mammal.
-
-
-
-
-
-
-
-
-
Search Results
94
records
(took 0.03 seconds)
